Related Experiment Video
Updated: Jun 27, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Direct and indirect costs for patients with myeloproliferative neoplasms
Jingbo Yu1, James Nelson2, Taylor Marlin2
1Incyte Corporation, Wilmington, DE, USA.
Abstract:
Myeloproliferative neoplasms (MPNs) are associated with substantial healthcare resource use and productivity loss. This retrospective cohort analysis used disability leave and medical claims data to measure direct and indirect healthcare costs associated with MPNs. The analysis included 173 patients with myelofibrosis (MF), 4477 with polycythemia vera (PV), 6061 with essential thrombocythemia (ET), and matched controls (n = 519, n = 13,431, and n = 18,183, respectively). Total healthcare costs were significantly higher for cases versus controls in each cohort (mean cost difference: MF, $67,456; PV, $10,970; ET, $22,279). Cases were more likely than controls to take disability leave and incurred higher disability-related costs. Among subgroups with thrombotic events, direct and indirect costs were higher for cases versus controls. Thrombotic events substantially increased direct costs and disability leave for patients with PV or ET compared with the full PV or ET cohorts. These findings demonstrate increased economic burden for patients with MPNs.
Insights
Myeloproliferative neoplasms (MPNs) significantly increase healthcare costs and productivity loss. Patients with MPNs incur higher direct medical expenses and disability-related costs compared to controls.
Area of Science:
- Hematology
- Health Economics
Background:
- Myeloproliferative neoplasms (MPNs) represent a group of disorders associated with significant morbidity.
- These conditions are known to impact healthcare resource utilization and economic productivity.
Purpose of the Study:
- To quantify the direct and indirect healthcare costs associated with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET).
- To assess the economic burden, including disability leave, for patients diagnosed with MPNs.
Main Methods:
- Retrospective cohort analysis utilizing disability leave and medical claims data.
- Comparison of healthcare costs between patients with MF, PV, ET, and matched control groups.
- Subgroup analysis for patients experiencing thrombotic events.
Main Results:
- Total healthcare costs were significantly higher for MPN cases compared to controls across all studied MPN types (MF: $67,456; PV: $10,970; ET: $22,279).
- MPN patients were more likely to take disability leave, incurring greater disability-related expenses.
- Thrombotic events further elevated direct and indirect costs in MPN subgroups, particularly for PV and ET.
Conclusions:
- Myeloproliferative neoplasms impose a substantial economic burden on healthcare systems and individuals.
- Disability and thrombotic events significantly contribute to the increased costs associated with MPNs.
- These findings highlight the need for comprehensive cost-management strategies in MPN care.
More Related Videos
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
Related Concept Videos
01:15Nursing Implementation
The five steps to implementing effective nursing care include reassessing the patient, reviewing and revising the existing nursing care plan, organizing the resources and care delivery, anticipating and preventing complications, and implementing nursing interventions.
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...